Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 29, 2007

View Archived Issues

Novel agents for treating diabetes and related disorders disclosed in recent patent literature

New agents with potential in the treatment of cancer disclosed in recent patent literature

New agents for musculoskeletal and connective tissue disorders disclosed in recent patents

Deterioration accelerated in amyotrophic lateral sclerosis patients given minocycline

MenACWY meningitis vaccine well tolerated, immunogenic in infants

Solvay reports third quarter 2007 results

Bristol-Myers Squibb advances growth hormone secretagogue to clinical development

Naryx Pharma completes enrollment in phase IIb clinical trial of Sybryx for chronic sinusitis

Xenome enters into joint research collaboration with Amylin for novel peptide therapeutics

Isis and Excaliard enter collaboration to develop antisense drugs for fibrotic diseases

Valeant completes enrollment of RESTORE2 phase III trial of retigabine for epilepsy

Xoma presents an update on the company's clinical development plans

Cyclacel presents an update on clinical development programs

Sustained improvement in SLE patients seen with belimumab over 2.5 years

Inhibition of soluble epoxide hydrolase protects against ischemic injury in vivo

AMT enters agreement with Digna and CIMA for program for late-stage liver cirrhosis

Pipex Pharmaceuticals enters CRADA to evaluate Coprexa for Huntington's disease

Israeli Government awards grant to Modigene for hGH-CTP development program

Fovea and Genzyme Corporation enter research collaboration in ophthalmology

CSL Behring reaches primary endpoint in IMPACT phase III clinical study of C1-INH

Osiris reports positive one-year interim results from phase I/II trial of Chondrogen

FDA accepts for filing UCB's NDA for Vimpat as adjunctive therapy in epilepsy

FDA accepts for filing UCB's NDA for Vimpat for diabetic neuropathic pain

FDA advisory committee to review Entereg NDA

Eisai submits Japanese NDA application for KES-524 for obesity management

E.U. approves Merck Serono's Cyanokit for cyanide poisoning

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...